Science Advances · 11 September 2026 · From issue 36
Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1
In mice, blocking a protein called SPP1 made immune therapy shrink KRAS-mutant lung tumors better.
Xin Zhang, Qian Hao et al.
Lung cancers with two specific gene changes, one in a gene called KRAS and one in a gene called TP53, respond better to immune therapy. The reason is a protein called SPP1. When both genes are mutated, SPP1 drops. Lower SPP1 lets more cancer-fighting immune cells enter the tumor and blocks fewer cells that would shut those fighters down.
Integrity screen: passed (3 checks) Checked 16 September 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue